Results 131 to 140 of about 14,165 (152)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A

Signal Transduction and Targeted Therapy, 2023
Javier Martinez-Trufero, Amancio Carnero, Daniel López López   +2 more
exaly  

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Journal of Clinical Oncology, 2021
Sibylle Loibl, Frederik Marmé, Miguel Martin   +2 more
exaly  

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Lancet Oncology, The, 2021
Erica L Mayer, Amylou C Dueck, Miguel Martin   +2 more
exaly  

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Lancet Oncology, The, 2016
Massimo Cristofanilli, Igor N Bondarenko, Seock-Ah Im   +2 more
exaly  

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Lancet Oncology, The, 2015
, Johannes Ettl, Marcus Schmidt
exaly  

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Science, 2019
Keelan Z Guiley, Jack W Stevenson, Kevin Lou   +2 more
exaly  

Palbociclib and Letrozole in Advanced Breast Cancer

New England Journal of Medicine, 2016
Richard S Finn, Miguel Martin, Hope S Rugo   +2 more
exaly  

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Lancet Oncology, The, 2022
exaly  

Treating cancer with selective CDK4/6 inhibitors

Nature Reviews Clinical Oncology, 2016

exaly  

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

New England Journal of Medicine, 2015
Fabrice Andre, Sherene Loi, Hiroji Iwata
exaly